Premium
Human Macrophage‐Activating Factors for Cytotoxicity
Author(s) -
Higuchi Masahiro,
Sugimoto Masamichi,
Kobayashi Yoshiro,
Osawa Toshiaki
Publication year - 1987
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1987.tb03109.x
Subject(s) - macrophage activating factor , cytotoxicity , macrophage , biology , lipopolysaccharide , monocyte , microbiology and biotechnology , monoclonal antibody , tumor necrosis factor alpha , immunology , antibody , in vitro , biochemistry
Human T cell hybridoma, H3‐E9–6, that produces macrophage activating factors for cytotoxicity (MAF‐C) was prepared by somatic fusion of phytohemagglutinin‐activated peripheral blood lymphocytes with emetine/actinomycin D‐treated cloned human acute lymphocytic leukemia cells (CEM 11). The activities of the following were assayed: (1) macrophage‐activating factor for cytotoxicity of monocytes (MAF‐C 1 day), (2) macrophage‐activating factor for cytotoxicity of monocyte‐derived macrophages (MAF‐C 6 day), (3) macrophage‐activating factor for cytotoxicity of murine macrophages (MAF‐Cm), (4) macrophage‐activating factor for glucose consumption (MAF‐G), (5) macrophage‐activating factor for O 2 ‐ formation (MAF‐O). The culture supernatant of H3‐E9–6 showed MAF‐C 1 day‐MAF‐C 6 day, MAF‐Cm, and MAF‐G activities. The MAF‐Cm activity was considerably enhanced by the addition of murine recombinant interferon gamma (rIFN‐ γ ). The MAF‐C 1 day activity in the H3‐E‐9–6 sup was not decreased by heat treatment (56 C, 30 min), by pH 2 treatment or by the addition of monoclonal anti‐human IFN‐ γ antibody or polymyxin B. These data suggest that MAF‐C in H3‐E9–6 sup is distinct from human IFN‐ γ or lipopolysaccharide (LPS).